Search

Your search keyword '"Gerassimos Tsourouflis"' showing total 3 results
Start Over Author "Gerassimos Tsourouflis" Language undetermined
3 results on '"Gerassimos Tsourouflis"'

1. Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma

Author

Antonios Kourtesis, Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Phivi Rondogianni, Vassilios Papadakis, Maria K. Angelopoulou, Gerassimos Tsourouflis, Vassilios Prassopoulos, Sophia Polychronopoulou, and Maria Efstathopoulou

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, Internal medicine, medicine, Classical Hodgkin lymphoma, Humans, Chemotherapy, business.industry, Lymphoma, Non-Hodgkin, food and beverages, Hematology, medicine.disease, Hodgkin Disease, Lymphoma, 030220 oncology & carcinogenesis, Relapsed refractory, Curative surgery, Hodgkin lymphoma, business, 030215 immunology
Abstract

At least 70–80% of the patients with Hodgkin lymphoma (HL) can be cured with first-line therapy with the improvement of staging methods and the introduction of increasingly effective chemotherapy r...

Published
2020

2. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database

Author

Fotios Panitsas, Christina Kalpadakis, Vassilios Xanthopoulos, Gerassimos Tsourouflis, Kostas Konstantopoulos, Eleftheria Hatzimichael, Stamatis Karakatsanis, Maria Dimou, Eleni Variamis, Maria Papaioannou, Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Sotirios G. Papageorgiou, Ioannis Kotsianidis, Meletios A. Dimopoulos, Alexia Piperidou, Ioannis Batsis, Ioannis Vassilopoulos, Evdoxia Hadjiharissi, Themistoklis Karmiris, Theoni Leonidopoulou, Maria K. Angelopoulou, Alkistis-Kyra Panteliadou, Eirini Katodritou, Panayiotis Panayiotidis, Dimitrios Boutsis, Maria Kotsopoulou, Niki Stavroyianni, Evgenia Verigou, and Michail Michail

Subjects
Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Databases, Factual, MEDLINE, Mediastinal Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Primary Mediastinal Large B-Cell Lymphoma, Survival rate, Hematology, business.industry, Follow up studies, medicine.disease, Prognosis, Hodgkin Disease, Lymphoma, Survival Rate, Hodgkin lymphoma, Female, Lymphoma, Large B-Cell, Diffuse, business, Follow-Up Studies
Published
2020

3. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance

Author

Maria N. Dimopoulou, Flora N. Kontopidou, Eleni Plata, Efstathios Koulieris, Panagiotis Panagiotidis, Gerassimos A. Pangalis, Maria K. Angelopoulou, Pantelis Tsirkinidis, Xanthi Yiakoumis, Maria Moschogiannis, Dimitra Rontogianni, Penelope Korkolopoulou, Sotirios Sachanas, Panagiotis Tsaftaridis, Christina Kalpadakis, Gerassimos Tsourouflis, Helen A. Papadaki, Marina P. Siakantaris, Theodoros P. Vassilakopoulos, Marie-Christine Kyrtsonis, and Stella I. Kokkoris

Subjects
Adult, Male, medicine.medical_specialty, Immunology, Treatment outcome, Kaplan-Meier Estimate, Biochemistry, Gastroenterology, Drug Administration Schedule, Maintenance Chemotherapy, 03 medical and health sciences, Remission induction, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Humans, Progression-free survival, Splenic marginal zone lymphoma, Aged, Retrospective Studies, Maintenance chemotherapy, Aged, 80 and over, business.industry, Splenic Neoplasms, Remission Induction, Follow up studies, Lymphoma, B-Cell, Marginal Zone, Cell Biology, Hematology, Middle Aged, medicine.disease, Progression-Free Survival, Lymphoma, Treatment Outcome, 030220 oncology & carcinogenesis, Drug Evaluation, Female, Rituximab, business, Follow-Up Studies, 030215 immunology, medicine.drug
Abstract

TO THE EDITOR: Treatment of splenic marginal zone lymphoma (SMZL) is not standardized due to the lack of prospective randomized trials.[1][1][⇓][2][⇓][3][⇓][4][⇓][5][⇓][6][⇓][7][⇓][8][⇓][9][⇓][10][⇓][11][⇓][12]-[13][13] After our initial 2007 paper, we now present updated data

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results